Research programme: anti-cancer therapeutics - Sorrento Therapeutics

Drug Profile

Research programme: anti-cancer therapeutics - Sorrento Therapeutics

Alternative Names: Anti-CD123 CAR-T cells; Anti-CD38 CAR-T cells; Anti-HAVCR2 mAbs - Sorrento; Anti-PD-1 mAbs - Sorrento Therapeutics; Anti-PD-L1 mAbs - Sorrento Therapeutics; Anti-TIM3 mAbs- Sorrento Therapeutics; CAR-T - TNK Therapeutics; CAR-T c-KIT; CAR-T GD3; CAR-T IL13R; STI 1014; STI 1110; STI-A0168; STI-A020X; STI-A050X; STI-A060X; STI-A1010; STI-A1011; STI-A1012; STI-A1014; STI-A1110; T-007; T-009

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC; Sorrento Therapeutics
  • Developer Sorrento Therapeutics; TNK Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; CD38 antigen inhibitors; Epidermal growth factor receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists; Ganglioside inhibitors; HAVCR2 protein inhibitors; Interleukin 13 expression modulators; Interleukin 13 inhibitors; Interleukin-3-receptor-alpha-subunit-antagonists; PDCD 1 protein inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Cancer; Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 01 Dec 2016 TNK Therapeutics announces intention to submit INDs to US FDA for anti-CD38 and anti-CD123 CAR-T programmes in H1 2017
  • 01 Dec 2016 Pharmacodynamics data from preclinical studies in Haematological malignancies (Mutiple myeloma, Acute myeloid leukaemia) released by TNK therapeutics
  • 01 Dec 2016 TNK therapeutics plans a first-in-human trial for anti-CD123 CAR-T programme in Haematological malignancies in H2 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top